Literature DB >> 14657195

Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency.

Bela F Asztalos1, Katalin V Horvath, Kouji Kajinami, Chorthip Nartsupha, Caitlin E Cox, Marcelo Batista, Ernst J Schaefer, Akihiro Inazu, Hiroshi Mabuchi.   

Abstract

Our purpose was to compare HDL subpopulations, as determined by nondenaturing two-dimensional gel electrophoresis followed by immunoblotting for apolipoprotein A-I (apoA-I), apoA-II, apoA-IV, apoCs, and apoE in heterozygous, compound heterozygous, and homozygous subjects for cholesteryl ester transfer protein (CETP) deficiency and controls. Heterozygotes, compound heterozygotes, and homozygotes had CETP masses that were 30, 63, and more than 90% lower and HDL-cholesterol values that were 64, 168, and 203% higher than those in controls, respectively. Heterozygotes had approximately 50% lower pre-beta-1 and more than 2-fold higher levels of alpha-1 and pre-alpha-1 particles than controls. Three of the five heterozygotes' alpha-1 particles also contained apoA-II, which was not seen in controls. Compound heterozygotes and homozygotes had very large particles not observed in controls and heterozygotes. These particles contained apoA-I, apoA-II, apoCs, and apoE. However, these subjects did not have decreased pre-beta-1 levels. Our data indicate that CETP deficiency results in the formation of very large HDL particles containing all of the major HDL apolipoproteins except for apoA-IV. We hypothesize that the HDL subpopulation profile of heterozygous CETP-deficient patients, especially those with high levels of alpha-1 containing apoA-I but no apoA-II, represent an improved anti-atherogenic state, although this might not be the case for compound heterozygotes and homozygotes with very large, undifferentiated HDL particles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14657195     DOI: 10.1194/jlr.M300198-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  16 in total

1.  Streptococcal serum opacity factor increases the rate of hepatocyte uptake of human plasma high-density lipoprotein cholesterol.

Authors:  Baiba K Gillard; Corina Rosales; Biju K Pillai; Hu Yu Lin; Harry S Courtney; Henry J Pownall
Journal:  Biochemistry       Date:  2010-10-25       Impact factor: 3.162

2.  Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence.

Authors:  B Greg Brown; Xue-Qiao Zhao; Marian C Cheung
Journal:  J Clin Lipidol       Date:  2007-02-15       Impact factor: 4.766

3.  Distinct Proteomic Signatures in 16 HDL (High-Density Lipoprotein) Subspecies.

Authors:  Jeremy D Furtado; Rain Yamamoto; John T Melchior; Allison B Andraski; Maria Gamez-Guerrero; Patrick Mulcahy; Zeling He; Tianxi Cai; W Sean Davidson; Frank M Sacks
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-12       Impact factor: 8.311

4.  Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

Authors:  Margaret E Brousseau; Margaret R Diffenderfer; John S Millar; Chorthip Nartsupha; Bela F Asztalos; Francine K Welty; Megan L Wolfe; Mats Rudling; Ingemar Björkhem; Bo Angelin; James P Mancuso; Andres G Digenio; Daniel J Rader; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-03-10       Impact factor: 8.311

5.  Enhancement by LDL of transfer of L-4F and oxidized lipids to HDL in C57BL/6J mice and human plasma.

Authors:  David Meriwether; Satoshi Imaizumi; Victor Grijalva; Greg Hough; Ladan Vakili; G M Anantharamaiah; Robin Farias-Eisner; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Ishaiahu Shechter
Journal:  J Lipid Res       Date:  2011-07-29       Impact factor: 5.922

Review 6.  Protection from Cardiovascular Disease Due to Increased High-Density Lipoprotein Cholesterol in African Black Populations: Myth or Reality?

Authors:  Nicholas J Woudberg; Julia H Goedecke; Sandrine Lecour
Journal:  Ethn Dis       Date:  2016-10-20       Impact factor: 1.847

7.  The two novel CETP mutations Gln87X and Gln165X in a compound heterozygous state are associated with marked hyperalphalipoproteinemia and absence of significant coronary artery disease.

Authors:  Jeffrey Rhyne; Michael J Ryan; Charles White; Theodore Chimonas; Michael Miller
Journal:  J Mol Med (Berl)       Date:  2006-07-20       Impact factor: 4.599

8.  Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.

Authors:  Gissette Reyes-Soffer; John S Millar; Colleen Ngai; Patricia Jumes; Ellie Coromilas; Bela Asztalos; Amy O Johnson-Levonas; John A Wagner; Daniel S Donovan; Wahida Karmally; Rajasekhar Ramakrishnan; Stephen Holleran; Tiffany Thomas; Richard L Dunbar; Emil M deGoma; Hashmi Rafeek; Amanda L Baer; Yang Liu; Michael E Lassman; David E Gutstein; Daniel J Rader; Henry N Ginsberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-03-10       Impact factor: 8.311

9.  High-density lipoprotein subpopulation profiles in lipoprotein lipase and hepatic lipase deficiency.

Authors:  Mariko Tani; Katalin V Horvath; Benoit Lamarche; Patrick Couture; John R Burnett; Ernst J Schaefer; Bela F Asztalos
Journal:  Atherosclerosis       Date:  2016-08-20       Impact factor: 5.162

10.  Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women.

Authors:  Stefania Lamon-Fava; Bela F Asztalos; Timothy D Howard; David M Reboussin; Katalin V Horvath; Ernst J Schaefer; David M Herrington
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-29       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.